Cargando…

A 46-Year-Old Thai Woman with Secondary Acquired Pure Red Cell Aplasia Due to Treatment with Recombinant Erythropoietin While on Dialysis for End-Stage Renal Disease Who Recovered Following ABO-Incompatible Kidney Transplantation

Patient: Female, 46-year-old Final Diagnosis: Pure red cell aplasia (PRCA) undergoing ABO-incompatible kidney transplantation Symptoms: End-stage kidney disease (ESKD) with anemia Medication:— Clinical Procedure: — Specialty: Nephrology OBJECTIVE: Rare disease BACKGROUND: Pure red cell aplasia (PRCA...

Descripción completa

Detalles Bibliográficos
Autores principales: Kitpermkiat, Rungthiwa, Thotsiri, Sansanee, Arpornsujaritkun, Nuttaporn, Sangkum, Premsant, Chantrathammachart, Pichika, Kitpoka, Pimpun, Thammanichanond, Duangtawan, Virankabutra, Tanist, Kantachuvesiri, Surasak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302208/
https://www.ncbi.nlm.nih.gov/pubmed/35842751
http://dx.doi.org/10.12659/AJCR.935451
Descripción
Sumario:Patient: Female, 46-year-old Final Diagnosis: Pure red cell aplasia (PRCA) undergoing ABO-incompatible kidney transplantation Symptoms: End-stage kidney disease (ESKD) with anemia Medication:— Clinical Procedure: — Specialty: Nephrology OBJECTIVE: Rare disease BACKGROUND: Pure red cell aplasia (PRCA) is an uncommon cause of anemia in end-stage kidney disease (ESKD). It is attributed to recombinant human erythropoietin (rHuEPO) administration. Although immunosuppression is the mainstay therapy, its effectiveness varies from 30% to 70%. PRCA in ESKD has been reported to improve following kidney transplantation. CASE REPORT: A 46-year-old woman with ESKD secondary to lupus nephritis was treated for uremia at our center. She developed severe anemia. Bone marrow aspiration and biopsy revealed a reduction of erythroid precursors, consistent with PRCA. Because she had no sibling’s blood group matched with her, ABO-incompatible kidney transplantation was an option for treatment. She underwent a desensitization protocol consisting of rituximab 375 mg/m(2), tacrolimus, mycophenolate mofetil, and prednisolone 4 weeks before surgery, in addition to 3 sessions of double-filtration plasmapheresis (DFPP) every other day followed by intravenous immunoglobulin (IVIG) and 1 session of specific immunoadsorption (Glycosorb(®) B column) at pre-transplant day −1. She also received low-dose rabbit anti-thymocyte globulin (rATG) (Thymoglobulin(®)) (total 2.0 mg/kg). Maintenance therapy included tacrolimus, mycophenolate mofetil, and prednisolone. Allograft function normalized a few days after transplantation and her Hb gradually increased. CONCLUSIONS: We report a rare case of PRCA in a patient with ESKD undergoing ABO-incompatible kidney transplantation. The outcome was satisfactory, with complete correction of anemia and kidney function.